Freenome builds blood tests that use multiomics and machine learning to catch cancer early, starting with colorectal cancer. Its stack spans PyTorch, JAX, DeepSpeed, Ray and Hugging Face across AWS, Azure and GCP, a heavy ML footprint for a diagnostics company, while job posts pair research-led hiring with a commercial push to win health-system contracts and drive screening adoption.
Notable leadership hires: Real World Data Director
Freenome is a privately held biotechnology company founded in 2014 and headquartered in Brisbane, California. It develops blood-based screening tests designed to detect cancer at early, more treatable stages, combining a multiomics platform with machine learning. Its first test targets early-stage colorectal cancer and advanced adenomas. The company employs 201–500 people and hires in the United States, with roles across research, product, sales, engineering and data.
Freenome uses Python, R Markdown, Julia and C++, ML frameworks like PyTorch, TensorFlow, JAX and Ray, orchestration with Flyte and Airflow, Kubernetes and Docker, and runs on AWS, Azure and GCP. It is adopting AWS EMR.
Yes. Research is Freenome's largest hiring area, skewed toward senior and staff-level roles, with additional openings in product, sales, engineering and data, all in the United States.
Freenome is developing clinical-grade assays, molecular signal identification models, a commercial data platform and data products, while optimizing NGS workflows and negotiating contracts with health systems.
Other companies in the same industry, closest in size
Freenome's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.
